The facts are staggering. Scientific studies have shown that people with hearing loss have up to a five hundred percent higher risk of dementia (including Alzheimer’s), as well as serious falls and clinical depression. Today, around six million Americans have Alzheimer’s—a number that is only expected to increase and overwhelm the healthcare system in the next five to seven years. In a groundbreaking presentation, Dr. Robert Keefer relies on thirty years of experience in the healthcare industry and the results of his meticulous research to offer insights on how to correct outdated Medicare policies, improve US hearing healthcare, and ensure well-performing hearing aids for everyone in need. After detailing why people with hearing loss don’t use hearing aids, he leads us on a journey into the world of these tiny medical devices, the US hearing healthcare matrix, the technology, and costs surrounding hearing aids, stories of those with hearing loss, wisdom from audiologists in their own words, and ways to advocate for changes that save hundreds of billions of dollars in healthcare expenses. The Alzheimer’s/Hearing Aid Paradox shares insights and facts from a hearing aid industry insider that point the way to lowering the risk and cost of Alzheimer’s by providing hearing aids for everyone in need. “With this book, the author has gifted us with a practical but ground-breaking way to reduce loneliness — and thus the risk of Alzheimer’s — by helping millions of Americans access high-performing hearing aids.” —George Vradenburg ,Chairman and Co-Founder, UsAgainstAlzheimer’s “This book presents a practical, no-nonsense way to better understand hearing loss and dementia and navigate hearing aid treatment options.” —Dr. Brian Taylor ,Senior Director of Audiology, Signia Hearing, Editor of Audiology Practices, Co-Author of Fitting and Dispensing Hearing Aids, 3rd Edition

The facts are staggering. Scientific studies have shown that people with hearing loss have up to a five hundred percent higher risk of dementia (including Alzheimer's), as well as serious falls and clinical depression. Today, around six million Americans have Alzheimer's--a number that is only expected to increase and overwhelm the healthcare system in the next five to seven years. In a groundbreaking presentation, Dr. Robert Keefer relies on thirty years of experience in the healthcare industry and the results of his meticulous research to offer insights on how to correct outdated Medicare policies, improve US hearing healthcare, and ensure well-performing hearing aids for everyone in need. After detailing why people with hearing loss don't use hearing aids, he leads us on a journey into the world of these tiny medical devices, the US hearing healthcare matrix, the technology, and costs surrounding hearing aids, stories of those with hearing loss, wisdom from audiologists in their own words, and ways to advocate for changes that save hundreds of billions of dollars in healthcare expenses. The Alzheimer's/Hearing Aid Paradox shares insights and facts from a hearing aid industry insider that point the way to lowering the risk and cost of Alzheimer's by providing hearing aids for everyone in need. "With this book, the author has gifted us with a practical but ground-breaking way to reduce loneliness -- and thus the risk of Alzheimer's -- by helping millions of Americans access high-performing hearing aids." --George Vradenburg ,Chairman and Co-Founder, UsAgainstAlzheimer's "This book presents a practical, no-nonsense way to better understand hearing loss and dementia and navigate hearing aid treatment options." --Dr. Brian Taylor ,Senior Director of Audiology, Signia Hearing, Editor of Audiology Practices, Co-Author of Fitting and Dispensing Hearing Aids, 3rd Edition

The instant New York Times and Wall Street Journal bestseller A groundbreaking plan to prevent and reverse Alzheimer’s Disease that fundamentally changes how we understand cognitive decline. Everyone knows someone who has survived cancer, but until now no one knows anyone who has survived Alzheimer's Disease. In this paradigm shifting book, Dale Bredesen, MD, offers real hope to anyone looking to prevent and even reverse Alzheimer's Disease and cognitive decline. Revealing that AD is not one condition, as it is currently treated, but three, The End of Alzheimer’s outlines 36 metabolic factors (micronutrients, hormone levels, sleep) that can trigger "downsizing" in the brain. The protocol shows us how to rebalance these factors using lifestyle modifications like taking B12, eliminating gluten, or improving oral hygiene. The results are impressive. Of the first ten patients on the protocol, nine displayed significant improvement with 3-6 months; since then the protocol has yielded similar results with hundreds more. Now, The End of Alzheimer’s brings new hope to a broad audience of patients, caregivers, physicians, and treatment centers with a fascinating look inside the science and a complete step-by-step plan that fundamentally changes how we treat and even think about AD.

We live in an aging world. Illnesses that are prevalent and cause significant morbidity and mortality in older people will consume an increasing share of health care resources. One such illness is depression. This illness has a particularly devastating impact in the elderly because it is often undiagnosed or inadequately treated. Depression not only has a profound impact on quality of life but it is associated with an increased risk of mortality from suicide and vascular disease. In fact for every medical illness studied, e.g. heart disease, diabetes, cancer, individuals who are depressed have a worse prognosis. Research has illuminated the physiological and behavioral effects of depression that accounts for these poor outcomes. The deleterious relationship between depression and other illnesses has changed the concept of late-life depression from a "psychiatric disorder" that is diagnosed and treated by a psychiatrist to a common and serious disorder that is the responsibility of all physicians who care for patients over the age of 60.This is the first volume devoted to the epidemiology, phenomenology, psychobiology, treatment and consequences of late-life depression. Although much has been written about depressive disorders, the focus has been primarily on the illness as experienced in younger adults. The effects of aging on the brain, the physiological and behavioral consequences of recurrent depression, and the impact of other diseases common in the elderly, make late-life depression a distinct entity. There is a compelling need for a separate research program, specialized treatments, and a book dedicated to this disorder. This book will be invaluable to psychiatrists, gerontologists, clinical psychologists, social workers, students, trainees, and others who care for individuals over the age of sixty.

The instant New York Times bestseller The New York Times Best Selling author of The End of Alzheimer's lays out a specific plan to help everyone prevent and reverse cognitive decline or simply maximize brainpower. In The End of Alzheimer's Dale Bredesen laid out the science behind his revolutionary new program that is the first to both prevent and reverse symptoms of Alzheimer's disease. Now he lays out the detailed program he uses with his own patients. Accessible and detailed, it can be tailored to anyone's needs and will enhance cognitive ability at any age. What we call Alzheimer's disease is actually a protective response to a wide variety of insults to the brain: inflammation, insulin resistance, toxins, infections, and inadequate levels of nutrients, hormones, and growth factors. Bredesen starts by having us figure out which of these insults we need to address and continues by laying out a personalized lifestyle plan. Focusing on the Ketoflex 12/3 Diet, which triggers ketosis and lets the brain restore itself with a minimum 12-hour fast, Dr. Bredesen drills down on restorative sleep, targeted supplementation, exercise, and brain training. He also examines the tricky question of toxic exposure and provides workarounds for many difficult problems. The takeaway is that we do not need to do the program perfectly but will see tremendous results if we can do it well enough. With inspiring stories from patients who have reversed cognitive decline and are now thriving, this book shifts the treatment paradigm and offers a new and effective way to enhance cognition as well as unprecedented hope to sufferers of this now no longer deadly disease.

The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias is an up-to-date and comprehensive overview of dementia for psychiatrists and other health care practitioners who deal with cognitively impaired adults in outpatient, inpatient, and long-term care settings. With content ranging from clinical guidance to basic research, it contains information on nearly every subject related to dementing conditions or illnesses -- not only providing extensive coverage of clinical management issues but also enabling a deeper understanding of the causes of dementia. Designed to assist the practitioner faced with everyday dilemmas, from dosages of antipsychotic drugs to legal and ethical issues, this textbook describes in detail the most common conditions and diseases leading to dementia and covers pharmacologic, behavioral, and environmental treatments. It also considers a broader range of cognitive disorders and impairment in order to help practitioners recognize and treat primary brain diseases and systemic disorders affecting the brain before they reach the stage of dementia. Building on the editors' earlier work The Dementias: Diagnosis, Treatment, and Research, this new book expands on its scope, with nearly twice the number of contributors -- all clinicians or researchers at the vanguard of the field. New to this edition are chapters on epidemiology, history of dementia, biomarkers for Alzheimer disease, care of the late-stage dementia patient, prevention of dementia, and chapters devoted to: Vascular cognitive impairment, emphasizing the importance of early detection with development of appropriate treatments and risk factor control Dementia with Lewy bodies and other synucleinopathies, describing differences in cognitive profile between synucleinopathies and Alzheimer disease Frontotemporal dementias, including behavioral and language variants Traumatic brain injury, distinguishing between proximal and distal effects and risk factors for dementia later in life An abundance of charts and illustrations, extensive references and additional readings, and chapter-end key points make this a practical volume for learning, while appendixes include easily administered instruments useful in daily practice for grading cognition, day-to-day function, neuropsychiatric symptoms, and quality of life. Whether used as a clinical guide or as a sourcebook on technical and scientific developments, The American Psychiatric Publishing Textbook of Alzheimer Disease and Other Dementias is an important reference for psychiatrists, neurologists, geriatricians, primary care physicians, and other health professionals who deal with cognitively impaired adults.